SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ — Imagenetix, Inc. (OTC Bulletin Board: IAGX – News), announced today the results for its third fiscal quarter ended December 31, 2006. Net sales for the third fiscal quarter were $1,062,000, a decrease of 39.1% from the $1,743,000 reported for the same period of the prior fiscal year. The Company [...]
{ Comments on this entry are closed }
SAN DIEGO–(BUSINESS WIRE)–Imagenetix, Inc. (OTCBB: IAGX – News) today announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has completed pre-IND assessment by the FDA Dental and Dermatology Division and received positive comments. The FDA response, issued after reviewing animal toxicity, [...]
{ Comments on this entry are closed }
SAN DIEGO–(BUSINESS WIRE)–Aug. 21, 2006–Imagenetix, Inc. (OTCBB: IAGX – News) today announced a comprehensive nationwide retail branding program for its proprietary products. The first products to be branded under the program will be the company’s Celadrin®-based joint health formulas. These products, branded under the name Inflame Away(TM), will be exclusively marketed by Imagenetix and sold [...]
{ Comments on this entry are closed }
SAN DIEGO–(BUSINESS WIRE)–June 26, 2006–Imagenetix, Inc. (OTCBB:IAGX – News) today announced it has engaged the services of Michael Hamrell, Ph.D., president of MORIAH Consultants, a regulatory affairs and clinical research consulting firm near Los Angeles. Dr. Hamrell, who has held leading positions within the FDA and NIH and served as a regulatory affairs and pharmaceutical [...]
{ Comments on this entry are closed }
SAN DIEGO–(BUSINESS WIRE)–June 1, 2006–Imagenetix Inc. (OTCBB: IAGX – News) today announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has achieved expected results in important baseline acute toxicity studies. In the first study, CD-1 mice were administered 1-TDC orally at [...]
{ Comments on this entry are closed }